Jazz Pharmaceuticals (JAZZ) Tax Provisions (2012 - 2026)

Jazz Pharmaceuticals' Tax Provisions history runs 15 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 134.27% year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was -$248.5 million, a 105.47% decrease from a year earlier, with the FY2025 full-year figure at -$272.4 million, down 197.98% from the prior year.
• Tax Provisions advanced to $6.1 million in Q1 2026 per JAZZ's latest filing, from $5.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $11.7 million in Q1 2024 and bottomed at -$242.4 million in Q3 2025.
• The 5-year median for Tax Provisions is -$17.8 million (2025), against an average of -$37.4 million.
• Across the five-year window, Tax Provisions slumped 2958.96% in 2023 and jumped 176.15% in 2024, its largest moves.
• Year by year, Tax Provisions stood at -$100.0 million in 2022, then surged by 66.91% to -$33.1 million in 2023, then tumbled by 75.01% to -$57.9 million in 2024, then surged by 108.56% to $5.0 million in 2025, then climbed by 23.06% to $6.1 million in 2026.
• Per Business Quant, the three latest JAZZ Tax Provisions figures stand at $6.1 million (Q1 2026), $5.0 million (Q4 2025), and -$242.4 million (Q3 2025).